Profound Medical Corp. Common Stock
PROFProfound Medical Corp. is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of various urological conditions. It specializes in minimally invasive, image-guided treatments, notably through its flagship platform for transurethral ultrasound-guided therapy. The company aims to provide effective and less invasive procedures that improve patient outcomes in areas such as benign prostatic hyperplasia (BPH).
Company News
Profound Medical Corp. successfully closed a $36 million registered direct offering of 5.14 million common shares at $7.00 per share. The company plans to use net proceeds for sales and marketing expansion, working capital, R&D, and strategic transactions. An additional $4 million private placement with Canadian purchasers is expected to close by...
Dr. Pejman Ghanouni from Stanford Medicine received a Cum Laude award at RSNA 2025 for presenting results from the CAPTAIN trial, comparing MRI-guided transurethral ultrasound ablation (TULSA) with robotic radical prostatectomy for prostate cancer treatment.
AI platform Profound has been recognized by Redpoint Ventures in their inaugural AI64 list, highlighting the company's innovative approach to AI-powered brand visibility and marketing optimization.
Profound, an AI visibility and content optimization platform, was selected for Redpoint Ventures' AI64 list, recognizing the most promising private AI companies. The platform serves over 10,000 marketers from 1,000 organizations and helps brands optimize their presence in AI-powered search results.
The global HIFU market is expected to grow rapidly over the next decade, driven by the rising demand for non-invasive therapeutic solutions and advancements in imaging technology. Key growth regions include Asia-Pacific and North America.
